PB
PBV.F Prestige Consumer Healthcare Inc
- Market cap
- EUR 1.98B
- P/E
- 15.0x
- P/B
- 1.06x
- ROE
- 5.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is PBV.F undervalued?
Graham numberPBV.F trades 16.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prestige Consumer Healthcare Inc fundamental analysis
No fundamental analysis for Prestige Consumer Healthcare Inc yet.
Prestige Consumer Healthcare Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Bu…
Full company profilePrestige Consumer Healthcare Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Prestige Consumer Healthcare Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 882M | 1.04B | 976M | 963M | 943M | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B | 1.20B |
| Gross Profit | 500M | 577M | 556M | 552M | 547M | 621M | 625M | 624M | 634M | 596M | 617M |
| Operating Income | 257M | 216M | 296M | 291M | 297M | 330M | 348M | 342M | 349M | 309M | 266M |
| EBITDA | - | 247M | 99.0M | 317M | 317M | 359M | 7.87M | 374M | 362M | 331M | 301M |
| Net Income | 69.4M | 340M | -35.8M | 142M | 165M | 205M | -82.3M | 209M | 215M | 190M | 109M |
| EPS | 1.31 | 6.40 | -0.69 | 2.84 | 3.30 | 4.08 | -1.66 | 4.20 | 4.33 | 4.02 | 2.30 |
| Balance Sheet | |||||||||||
| Total Assets | 3.91B | 3.76B | 3.44B | 3.51B | 3.43B | 3.67B | 3.35B | 3.32B | 3.40B | 3.49B | 4.72B |
| Total Liabilities | 3.09B | 2.58B | 2.35B | 2.34B | 2.07B | 2.09B | 1.91B | 1.66B | 1.57B | 1.61B | 2.78B |
| Shareholders' Equity | 823M | 1.18B | 1.10B | 1.17B | 1.36B | 1.58B | 1.45B | 1.66B | 1.83B | 1.89B | 1.94B |
| Cash & Short-term Investments | 41.9M | 32.5M | 27.5M | 94.8M | 32.3M | 27.2M | 58.5M | 46.5M | 97.9M | 63.9M | 46.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 149M | 210M | 189M | 217M | 236M | 260M | 230M | 249M | 252M | 258M | 217M |
| Capital Expenditure | 2.98M | 12.5M | 10.5M | 14.6M | 22.2M | 9.64M | 7.78M | 9.55M | 8.22M | 11.2M | 14.7M |
| Free Cash Flow | - | 198M | 179M | 200M | 213M | 250M | 222M | 239M | 243M | 246M | 203M |
| Ratios | |||||||||||
| ROE | 8.4% | 28.8% | -3.3% | 12.2% | 12.1% | 13.0% | -5.7% | 12.6% | 11.7% | 10.1% | 5.6% |
| ROA | 1.8% | 9.0% | -1.0% | 4.0% | 4.8% | 5.6% | -2.5% | 6.3% | 6.3% | 5.4% | 2.3% |
| Net Profit Margin | 7.9% | 32.6% | -3.7% | 14.8% | 17.5% | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% | 9.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Prestige Consumer Healthcare Inc dividends
Prestige Consumer Healthcare Inc has not paid dividends in the last 9 fiscal years.
Who owns Prestige Consumer Healthcare Inc
- Insiders 1.41%
- Institutions 98.59%
- Public & others 0.00%
- Shares outstanding 47.4M
- Free float 46.7M
Prestige Consumer Healthcare Inc company profile
- Company name
- Prestige Consumer Healthcare Inc
- Ticker
- PBV.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 890
- Fiscal year end
- March
- Address
- 660 White Plains Road, Tarrytown, NY, United States, 10591
- Phone
- 914 524 6800
- Website
- prestigebrands.com
About Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Prestige Consumer Healthcare Inc management
7- Mr. Ronald M. Lombardi CPAChairman, President & CEO · born 1964
- Ms. Christine Sacco CPACFO & COO · born 1976
- Mr. William C. P'Pool J.D.Senior VP, General Counsel & Corporate Secretary · born 1965
- Mr. Adel MekhailExecutive Vice President of Marketing & Sales · born 1961
- Mr. Philip David Terpolilli C.F.A.Director of Investor Relations
- Dean SiegalDirector of Communications
- Mr. Jose Luis RosadoSenior Vice President of Quality & Regulatory Affairs